Inhibition of RAS function through targeting an allosteric regulatory site

Nature Chemical Biology

Volumn 13, Issue 1, 2017, Pages 62-68

  Spencer Smith, Russell ^a,b   Koide, Akiko ^c,d   Zhou, Yong ^e   Eguchi, Raphael R ^c   Sha, Fern ^c   Gajwani, Priyanka ^a   Santana, Dianicha ^a   Gupta, Ankit ^c,d   Jacobs, Miranda ^a   Herrero Garcia, Erika ^a,b   Cobbert, Jacqueline ^a   Lavoie, Hugo ^f   Smith, Matthew ^g   Rajakulendran, Thanashan ^h,i   Dowdell, Evan ^c   Okur, Mustafa Nazir ^a   Dementieva, Irina ^c   Sicheri, Frank ^h,i   Therrien, Marc ^f   Hancock, John F ^e   Ikura, Mitsuhiko ^g   Koide, Shohei ^c,d   O'Bryan, John P ^a,b   more..

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Jesse Brown Medical Center   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; K RAS PROTEIN; NS1 BINDING PROTEIN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RAS PROTEIN;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; ENZYME INHIBITION; ONCOGENE H RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ALLOSTERIC SITE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS CELL LINE; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; NIH 3T3 CELL LINE;

ALLOSTERIC SITE; ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; HEK293 CELLS; HUMANS; MICE; NIH 3T3 CELLS; RAS PROTEINS;

EID: 84994559220     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2231     Document Type: Article

References (60)

1. Karnoub, A. E., Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531 (2008).
2. Cox, A. D., Der, C. J. Ras history: The saga continues. Small GTPases 1, 2-27 (2010).
3. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
4. Leshchiner, E. S., et al. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc. Natl. Acad. Sci. USA 112, 1761-1766 (2015).
5. Patgiri, A., Yadav, K. K., Arora, P. S., Bar-Sagi, D. An orthosteric inhibitor of the Ras-Sos interaction. Nat. Chem. Biol. 7, 585-587 (2011).
6. Koide, A., Bailey, C. W., Huang, X., Koide, S. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284, 1141-1151 (1998).
7. Koide, A., Wojcik, J., Gilbreth, R. N., Hoey, R. J., Koide, S. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J. Mol. Biol. 415, 393-405 (2012).
8. Koide, S., Koide, A., Lipovšek, D. Target-binding proteins based on the 10th human fibronectin type III domain (10Fn3). Methods Enzymol. 503, 135-156 (2012).
9. Sha, F., et al. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc. Natl. Acad. Sci. USA 110, 14924-14929 (2013).
10. Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., Der, C. J. Drugging the undruggable RAS: mission possible Nat. Rev. Drug Discov. 13, 828-851 (2014).
11. Wong, K. A., et al. A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2) regulation. PLoS One 7, e45360 (2012).
12. Chiu, V. K., et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4, 343-350 (2002).
13. Colicelli, J. Human RAS superfamily proteins and related GTPases. Sci. STKE 2004, 13 (2004).
14. Burns, M. C., et al. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl. Acad. Sci. USA 111, 3401-3406 (2014).
15. Feramisco, J. R., et al. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature 314, 639-642 (1985).
16. Fetics, S. K., et al. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23, 505-516 (2015).
17. Margarit, S. M., et al. Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112, 685-695 (2003).
18. Hall, B. E., Bar-Sagi, D., Nassar, N. The structural basis for the transition from Ras-GTP to Ras-GDP. Proc. Natl. Acad. Sci. USA 99, 12138-12142 (2002).
19. Scheffzek, K., et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338 (1997).
20. Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., Kuriyan, J. The structural basis of the activation of Ras by Sos. Nature 394, 337-343 (1998).
21. Sun, Q., et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Edn. Engl. 51, 6140-6143 (2012).
22. Güldenhaupt, J., et al. N-Ras forms dimers at POPC membranes. Biophys. J. 103, 1585-1593 (2012).
23. Abankwa, D., et al. A novel switch region regulates H-ras membrane orientation and signal output. EMBO J. 27, 727-735 (2008).
24. Plowman, S. J., Muncke, C., Parton, R. G., Hancock, J. F. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc. Natl. Acad. Sci. USA 102, 15500-15505 (2005).
25. Zhou, Y., et al. Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling. Science 349, 873-876 (2015).
26. Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
27. Freeman, A. K., Ritt, D. A., Morrison, D. K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 49, 751-758 (2013).
28. Zhou, Y., et al. Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters. Mol. Cell. Biol. 34, 862-876 (2014).
29. Plowman, S. J., Ariotti, N., Goodall, A., Parton, R. G., Hancock, J. F. Electrostatic interactions positively regulate K-Ras nanocluster formation and function. Mol. Cell. Biol. 28, 4377-4385 (2008).
30. Yan, J., Roy, S., Apolloni, A., Lane, A., Hancock, J. F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273, 24052-24056 (1998).
31. Lim, S. M., et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Edn Engl. 53, 199-204 (2014).
32. Shima, F., et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl. Acad. Sci. USA 110, 8182-8187 (2013).
33. Wu, X., Upadhyaya, P., Villalona-Calero, M. A., Briesewitz, R., Pei, D. Inhibition of Ras-Effector Interaction by Cyclic Peptides. MedChemComm 4, 378-382 (2013).
34. Zhang, X., et al. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450, 741-744 (2007).
35. Herrero, A., et al. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 28, 170-182 (2015).
36. Santos, E., Nebreda, A. R., Bryan, T., Kempner, E. S. Oligomeric structure of p21 ras proteins as determined by radiation inactivation. J. Biol. Chem. 263, 9853-9858 (1988).
37. Inouye, K., Mizutani, S., Koide, H., Kaziro, Y. Formation of the Ras dimer is essential for Raf-1 activation. J. Biol. Chem. 275, 3737-3740 (2000).
38. Nan, X., et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc. Natl. Acad. Sci. USA 112, 7996-8001 (2015).
39. Nan, X., et al. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc. Natl. Acad. Sci. USA 110, 18519-18524 (2013).
40. Muratcioglu, S., et al. GTP-Dependent K-Ras Dimerization. Structure 23, 1325-1335 (2015).
41. Kovrigina, E. A., Galiakhmetov, A. R., Kovrigin, E. L. The Ras G Domain Lacks the Intrinsic Propensity to Form Dimers. Biophys. J. 109, 1000-1008 (2015).
42. Mazhab-Jafari, M. T., et al. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Proc. Natl. Acad. Sci. USA 112, 6625-6630 (2015).
43. Kunkel, T. A., Roberts, J. D., Zakour, R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154, 367-382 (1987).
44. Gilbreth, R. N., et al. Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design. Proc. Natl. Acad. Sci. USA 108, 7751-7756 (2011).
45. Minor, W., Cymborowski, M., Otwinowski, Z., Chruszcz, M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 62, 859-866 (2006).
46. McCoy, A. J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
47. Emsley, P., Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
48. Adams, P. D., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
49. Chen, V. B., et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
50. The PyMOL Molecular Graphics System v. 1. 8 (Schrödinger, LLC, 2015).
51. Reynolds, C., Damerell, D., Jones, S. ProtorP: a protein-protein interaction analysis server. Bioinformatics 25, 413-414 (2009).
52. Lawrence, M. C., Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
53. Taylor, S. J., Resnick, R. J., Shalloway, D. Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. Methods Enzymol. 333, 333-342 (2001).
54. Bondzi, C., Grant, S., Krystal, G. W. A novel assay for the measurement of Raf-1 kinase activity. Oncogene 19, 5030-5033 (2000).
55. Pai, E. F., et al. Refined crystal structure of the triphosphate conformation of H-ras p21 at 1. 35 A resolution: implications for the mechanism of GTP hydrolysis. EMBO J. 9, 2351-2359 (1990).
56. Krissinel, E., Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
57. Lavoie, H., et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat. Chem. Biol. 9, 428-436 (2013).
58. Abe, K., et al. Vav2 is an activator of Cdc42, Rac1, and RhoA. J. Biol. Chem. 275, 10141-10149 (2000).
59. Prior, I. A., Muncke, C., Parton, R. G., Hancock, J. F. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J. Cell Biol. 160, 165-170 (2003).
60. Prior, I. A., Parton, R. G., Hancock, J. F. Observing cell surface signaling domains using electron microscopy. Sci. STKE 2003, PL9 (2003).